AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Account Payables
Amounts the company owes suppliers for goods and services received.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Account Payables · Q3 FY2025 · quarter ended Sep 2025
Account payables of €7.58M in Q3 FY2025
Q3 FY2025 account payables was €7.58M.
Context
- Account payables amounted to 4.6% of total assets at the end of Q3 FY2025.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
Currency unavailable · from the balance sheet
No Account Payables data reported for this period type.
Account Payables vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Account payables amounts to 4.6% of total assets for AGMB, versus a peer median of 2.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $14.73M USD | +131.8% | +8.3% | 7.4% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $12.8M USD | -14.6% | +80.4% | 2.3% |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €7.58M EUR | — | — | 4.6% |
| Mar 2026 | $7.52M USD | +22.8% | +11.6% | 2.3% | |
| Mar 2026 | $1.3M USD | -57.7% | -42.5% | 2.1% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | +4.1% | +10.0% | 2.3% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.